BACKGROUND: Anti-complement factor H (anti-CFH) antibody-associated hemolytic uremic syndrome (HUS) is an important cause of acute kidney injury in Indian children. While management comprises plasma exchange and immunosuppression, information on the impact on serial antibody titers and outcomes is limited. METHODS: This retrospective study included 45 patients with anti-CFH-associated HUS who were followed for ≥12 months. Following the initial plasma exchange sessions, patients received prednisolone and either intravenous (IV) cyclophosphamide (n = 31) or IV rituximab (n = 14), followed by maintenance immunosuppression. RESULTS: The median anti-CFH antibody titers fell from 3,215.5 [interquartile range (IQR) 1,977.9-8,453.9 to 414.6 (IQR 251.6-1,368.2) AU/ml with plasma exchange therapy (P < 0.0001), and the decline was similar with three, five, or seven plasma exchange sessions (P = 0.08). Serial anti-CFH titers were similar in patients receiving IV cyclophosphamide- and rituximab-based regimens during the 12-month follow-up (P = 0.63). Renal outcomes and relapse frequencies at the 15.4-month follow-up were comparable. Seven patients relapsed 6.5 (IQR 2.2-12.3) months from treatment onset. Patients with relapse had higher antibody titers during remission (P = 0.017). Titers of ≥1,300 AU/ml at 6 months predicted subsequent relapses. CONCLUSIONS: Our patients with anti-CFH antibody-associated HUS showed a significant fall in antibody titers following daily plasma exchange sessions. Therapy with cyclophosphamide- or rituximab-based regimens was associated with similar outcomes and a comparable decline in antibody titers.
BACKGROUND: Anti-complement factor H (anti-CFH) antibody-associated hemolytic uremic syndrome (HUS) is an important cause of acute kidney injury in Indian children. While management comprises plasma exchange and immunosuppression, information on the impact on serial antibody titers and outcomes is limited. METHODS: This retrospective study included 45 patients with anti-CFH-associated HUS who were followed for ≥12 months. Following the initial plasma exchange sessions, patients received prednisolone and either intravenous (IV) cyclophosphamide (n = 31) or IV rituximab (n = 14), followed by maintenance immunosuppression. RESULTS: The median anti-CFH antibody titers fell from 3,215.5 [interquartile range (IQR) 1,977.9-8,453.9 to 414.6 (IQR 251.6-1,368.2) AU/ml with plasma exchange therapy (P < 0.0001), and the decline was similar with three, five, or seven plasma exchange sessions (P = 0.08). Serial anti-CFH titers were similar in patients receiving IV cyclophosphamide- and rituximab-based regimens during the 12-month follow-up (P = 0.63). Renal outcomes and relapse frequencies at the 15.4-month follow-up were comparable. Seven patients relapsed 6.5 (IQR 2.2-12.3) months from treatment onset. Patients with relapse had higher antibody titers during remission (P = 0.017). Titers of ≥1,300 AU/ml at 6 months predicted subsequent relapses. CONCLUSIONS: Our patients with anti-CFH antibody-associated HUS showed a significant fall in antibody titers following daily plasma exchange sessions. Therapy with cyclophosphamide- or rituximab-based regimens was associated with similar outcomes and a comparable decline in antibody titers.
Authors: Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl Journal: Pediatr Nephrol Date: 2008-09-18 Impact factor: 3.714
Authors: Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi Journal: Clin J Am Soc Nephrol Date: 2010-07-01 Impact factor: 8.237
Authors: Marie-Agnès Dragon-Durey; Sidharth Kumar Sethi; Arvind Bagga; Caroline Blanc; Jacques Blouin; Bruno Ranchin; Jean-Luc André; Nobuaki Takagi; Hae Il Cheong; Pankaj Hari; Moglie Le Quintrec; Patrick Niaudet; Chantal Loirat; Wolf Herman Fridman; Véronique Frémeaux-Bacchi Journal: J Am Soc Nephrol Date: 2010-11-04 Impact factor: 10.121
Authors: Mihály Józsi; Christoph Licht; Stefanie Strobel; Svante L H Zipfel; Heiko Richter; Stefan Heinen; Peter F Zipfel; Christine Skerka Journal: Blood Date: 2007-11-15 Impact factor: 22.113
Authors: Iain Moore; Lisa Strain; Isabel Pappworth; David Kavanagh; Paul N Barlow; Andrew P Herbert; Christoph Q Schmidt; Scott J Staniforth; Lucy V Holmes; Roy Ward; Lynn Morgan; Timothy H J Goodship; Kevin J Marchbank Journal: Blood Date: 2009-10-27 Impact factor: 22.113
Authors: Lianne M Geerdink; Dineke Westra; Joanna A E van Wijk; Eiske M Dorresteijn; Marc R Lilien; Jean-Claude Davin; Martin Kömhoff; Koen Van Hoeck; Amerins van der Vlugt; Lambertus P van den Heuvel; Nicole C A J van de Kar Journal: Pediatr Nephrol Date: 2012-03-13 Impact factor: 3.714
Authors: Agnes Hackl; Rasmus Ehren; Michael Kirschfink; Peter F Zipfel; Bodo B Beck; Lutz T Weber; Sandra Habbig Journal: Pediatr Nephrol Date: 2017-02-20 Impact factor: 3.714
Authors: Vicky Brocklebank; Sally Johnson; Thomas P Sheerin; Stephen D Marks; Rodney D Gilbert; Kay Tyerman; Meredith Kinoshita; Atif Awan; Amrit Kaur; Nicholas Webb; Shivaram Hegde; Eric Finlay; Maggie Fitzpatrick; Patrick R Walsh; Edwin K S Wong; Caroline Booth; Larissa Kerecuk; Alan D Salama; Mike Almond; Carol Inward; Timothy H Goodship; Neil S Sheerin; Kevin J Marchbank; David Kavanagh Journal: Kidney Int Date: 2017-07-24 Impact factor: 10.612